Bionic Pancreas: Closer to Fully Automated Insulin Delivery?
-
The investigational insulin-only iLet Bionic Pancreas (Beta Bionics) reduced A1c without increasing hypoglycemia in adults and children with type 1 diabetes with greater automation than currently available hybrid closed-loop or artificial pancreas insulin delivery systems. Results from the pivotal multicenter Insulin-Only Bionic Pancreas Pivotal Trial were presented during a 1-hour symposium on June 3 at the American Diabetes Association (ADA) 82nd Scientific Sessions.
-
@malkeet-singh Automated insulin delivery systems comprise an insulin pump, a continuous glucose monitor (CGM), and a software algorithm connecting the two devices. The iLet pivotal trial is the largest randomized clinical trial to date of any automated insulin delivery system and enrolled a more diverse population of people with type 1 diabetes, including more from minority groups, and those with higher baseline A1c levels than in previous trials. The data have been submitted to the US Food and Drug Administration (FDA), which granted the iLet a breakthrough device designation in December 2019.